Letter | Published:

Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor

Naturevolume 302pages832837 (1983) | Download Citation

Subjects

Abstract

Although histaminergic neurones have not yet been histochemically visualized, there is little doubt that histamine (HA) has a neurotransmitter role in the invertebrate and mammalian central nervous system1,2. For example, a combination of biochemical, electrophysiological and lesion studies in rats have shown that histamine is synthesized in and released from a discrete set of neurones ascending through the lateral hypothalamic area and widely projecting in the telencephalon3–5. Histamine acts on target cells in mammalian brain via stimulation of two classes of receptor (H1 and H2) previously characterized in peripheral organs6,7 and probably uses Ca2+ and cyclic AMP, respectively, as second messengers8–10. It is well established that several neurotransmitters affect neuronal activity in the central nervous system through stimulation not only of postsynaptic receptors, but also of receptors located presynaptically which often display distinct pharmacological specificity and by which they may control their own release. Such ‘autoreceptors’ have been demonstrated (or postulated) in the case of noradrenaline, dopamine, serotonin, acetylcholine and γ-aminobutyric acid (GABA) neurones11,12 but have never been demonstrated for histamine. We show here that histamine inhibits its own release from depolarized slices of rat cerebral cortex, an action apparently mediated by a class of receptor (H3) pharmacologically distinct from those previously characterized, that is, the H1 and H2 receptors.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Weinreich, D. in Biochemistry of Characterised Neurons (ed. Osborne, C. N. N.) 153–175 (Pergamon, Oxford, 1977).

  2. 2

    Schwartz, J. C., Pollard, H. & Quach, T. T. J. Neurochem. 35, 26–33 (1980).

  3. 3

    Garbarg, M., Barbin, G., Feger, J. & Schwartz, J. C. Science 186, 833–835 (1974).

  4. 4

    Barbin, G., Garbarg, M., Schwartz, J. C. & Storm-Mathisen, J. J. Neurochem. 26, 259–263 (1976).

  5. 5

    Haas, H. L. & Wolf, P. Pflügers Arch. ges. Physiol. 362, 38 (1976).

  6. 6

    Ash, A. S. F. & Schild, H. O. Br. J. Pharmac. Chemother. 27, 427–439 (1966).

  7. 7

    Black, J. W., Duncan, W. A. M., Durant, C. J., Ganellin, C. R. & Parsons, M. E. Nature 236, 385–390 (1972).

  8. 8

    Quach, T. T., Duchemin, A. M., Rose, C. & Schwartz, J. C. Molec. Pharmac. 17, 301–308 (1980).

  9. 9

    Palacios, J. M., Garbarg, M., Barbin, G. & Schwartz, J. C. Molec. Pharmac. 14, 971–982 (1978).

  10. 10

    Hegstrand, L. R., Kanof, P. D. & Greengard, P. Nature 260, 163–165 (1976).

  11. 11

    Langer, S. Z. Br. J. Pharmac. 60, 481–498 (1977).

  12. 12

    Starke, K. A. Rev. Pharmac. Tox. 21, 7–30 (1981).

  13. 13

    Baudry, M., Martres, M. P. & Schwartz, J. C. J. Neurochem. 21, 1301–1309 (1973).

  14. 14

    Garbarg, M., Barbin, G., Bischoff, S., Pollard, H. & Schwartz, J. C. Brain Res. 106, 333–348 (1976).

  15. 15

    Barbin, G., Hirsch, J.-C., Garbarg, M. & Schwartz, J. C. Brain Res. 92, 170–174 (1975).

  16. 16

    Verdière, M., Rose, C. & Schwartz, J. C. Eur. J. Pharmac. 34, 157–168 (1975).

  17. 17

    Tuomisto, L., Tuomisto, J. & Walaszek, E. J. Med. Biol. 53, 40–46 (1975).

  18. 18

    Subramanian, N. & Mulder, A. H. Eur. J. Pharmac. 35, 203–206 (1976).

  19. 19

    Biggs, M. J. & Johnson, E. S. Br. J. Pharmac. 70, 555–560 (1980).

  20. 20

    Subramanian, N. Life Sci. 31, 557–562 (1982).

  21. 21

    Taylor, K. M. & Snyder, S. H. J. Neurochem. 21, 1215–1223 (1973).

  22. 22

    Schwartz, J. C., Lampart, C. & Rose, C. J. Neurochem. 19, 801–810 (1972).

  23. 23

    Schwartz, J. C., Lampart, C. & Rose, C. J. Neurochem. 17, 1527–1534 (1970).

  24. 24

    Durant, G. J. et al. Nature 276, 403–405 (1978).

  25. 25

    Cheng, Y. C. & Prusoff, W. H. Biochem. Pharmac. 22, 3099–3108 (1973).

  26. 26

    Ganellin, C. R. in Pharmacology of Histamine Receptors (eds Ganellin, C. R. & Parsons, M. E.) 10–102 (Wright PSG, Bristol, 1982).

  27. 27

    Schwartz, J. C. et al. in Pharmacology of Histamine Receptors (eds Ganellin, C. R. & Parsons, M. E.) 351–391 (Wright PSG, Bristol, 1982).

  28. 28

    Yellin, T. O., Buck, S. H., Gilman, D. J., Jones, D. F. & Wardleworth, J. M. Life Sci. 25, 2001–2009 (1979).

  29. 29

    Parsons, M. E., Blakemore, R. C., Durant, G. J., Ganellin, C. R. & Rasmussen, A. C. Ag. Actions 5, 464 (1975).

  30. 30

    Trung Tuong, M. D., Garbarg, M. & Schwartz, J. C. Nature 287, 548–551 (1980).

  31. 31

    Black, J. W., Gerskowitch, V. P. & Leff, P. in Pharmacology of Histamine Receptors (eds Ganellin, C. R. & Parsons, M. E.) 1–9 (Wright PSG, Bristol, 1982).

  32. 32

    Dismukes, K., Rogers, M. & Daly, J. W. J. Neurochem. 26, 785–790 (1976).

  33. 33

    Werner, J., Van Der Lugt, J.-C., De Langen, C. D. J. & Mulder, A. H. J. Pharmac. exp. Ther. 211, 445–451 (1979).

  34. 34

    Dolphin, A., Adrien, J., Hamon, M. & Bockaert, J. Molec. Pharmac. 15, 1–15 (1979).

  35. 35

    Mounsey, I., Brady, K. A., Carroll, J., Fisher, R. & Middlemiss, D. N. Biochem. Pharmac. 31, 49–53 (1982).

  36. 36

    Quach, T. T., Rose, C., Duchemin, A. M. & Schwartz, J. C. Nature 298, 373–375 (1982).

  37. 37

    Snyder, S. H., Baldessarini, R. J. & Axelrod, J. J. Pharmac. exp. Ther. 153, 544–549 (1966).

  38. 38

    Parker, R. B. & Waud, D. R. J. Pharmac. exp. Ther. 177, 1–12 (1971).

Download references

Author information

Affiliations

  1. Unité de Neurobiologie U109, Centre Paul Broca de l'INSERM, 2ter, rue d'Alésia, 75014, Paris, France

    • Jean-Michel Arrang
    • , Monique Garbarg
    •  & Jean-Charles Schwartz

Authors

  1. Search for Jean-Michel Arrang in:

  2. Search for Monique Garbarg in:

  3. Search for Jean-Charles Schwartz in:

About this article

Publication history

Received

Accepted

Issue Date

DOI

https://doi.org/10.1038/302832a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.